Analysis of 1,115 patients tested for MET amplifi cation and therapy response in the MD anderson phase I clinic

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6336-6345

  Jardim, Denis L F ^a   Tang, Chad ^b   Gagliato, Debora De Melo ^a   Falchook, Gerald S ^a   Hess, Kenneth ^b   Janku, Filip ^a   Fu, Siqing ^a   Wheler, Jennifer J ^a   Zinner, Ralph G ^a   Naing, Aung ^a   Tsimberidou, Apostolia M ^a   Holla, Vijay Kumar ^b   Li, Marylin M ^c   Roy Chowdhuri, Sinchita ^b   Luthra, Raja ^b   Salgia, Ravi ^d   Kurzrock, Razelle ^e   Meric Bernstam, Funda ^a   Hong, David S ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; B RAF KINASE; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR;

ADENOCARCINOMA; ADOLESCENT; ADRENAL TUMOR; ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; BRAF GENE; BREAST CANCER; CANCER GRADING; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY TUMOR; MAJOR CLINICAL STUDY; MALE; MET GENE; METASTASIS; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PREVALENCE; PROTEIN DEPLETION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER STAGING; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; PROGNOSIS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; GENE AMPLIFICATION; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TEXAS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919703143     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1293     Document Type: Article

References (47)

1. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
2. Appleman LJ. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 2011;29:4837-8.
3. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 2012;18:1118-22.
4. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47: 1025-37.
5. Yeh CY, Shin SM, Yeh HH, Wu TJ, Shin JW, Chang TY, et al. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 2011;11:139.
6. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-82.
7. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, et al. MET ampli fication identifies a small and aggressive subgroup of esophagogastric adenocarcinomawith evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-10.
8. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26.
9. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RS. Gene ampli fication in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22.
10. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
11. Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP. Analysis of EGFR, EML4- ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. Exp Lung Res 2013;39:328-35.
12. Umeki K, Shiota G, Kawasaki H. Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology 1999;56: 314-21.
13. Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, et al. Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis. PloS ONE 2014;9:e84502.
14. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
15. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET Receptor Drives Resistance to Anti- EGFR Therapies in Colorectal Cancer. Cancer Discov 2013;3: 658-73.
16. Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009;20:298-304.
17. Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 2012;107:793-9.
18. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012;9:314-26.
19. Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 2012;30:3287-96.
20. Varella-Garcia M. Strati fi cation of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006;1:19.
21. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene ampli fi cation is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008;265: 258-69.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
24. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/ VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31:181-6.
25. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Ampli fi cation of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998;78:1143-53.
26. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene ampli fication and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 2011;24:1146-55.
27. Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, et al. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol 2013;42:1151-8.
28. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011;29:4789-95.
29. Jacobsen F, Ashtiani SN, Tennstedt P, Heinzer H, Simon R, Sauter G, et al. High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Exp Ther Med 2013;5: 102-6.
30. Inanc M, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol 2014;31:801.
31. Ai T, Wang N, Li WW, Song LP. Clinicopathological features and prognostic implications of EGFR/c-Met gene copy number and protein expression in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2010;32:825-9.
32. Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013;24:343-9.
33. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fi broblast-derived modulator of epithelial cell mobility. Nature 1987;327:239-42.
34. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990;111:2097-108.
35. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000; 19:1547-55.
36. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, et al. Overexpression and amplifi cation of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1: 147-54.
37. Lee SJ, Lee J, Sohn I, Mao M, Kai W, Park CK, et al. A survey of c-MET expression and amplifi cation in 287 patients with hepatocellular carcinoma. Anticancer Res 2013;33:5179-86.
38. Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C, et al. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch 2013;462:65-72.
39. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11:2312-9.
40. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
41. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-97.
42. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904.
43. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993;90:1937-41.
44. Forde PM, Kelly RJ. Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies. Oncologist 2013; 18:823-32.
45. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res 2014;20:1666-75.
46. Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib { +/-} onartuzumab in advanced non-small-cell lung cancer: MET expression levels are predictive of patient bene fit. Clin Cancer Res 2014;20:4488-98.
47. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 2013;31: 4445-52.